



(51) International Patent Classification:

A61K 31/4155 (2006.01) A61P 3/06 (2006.01)
A61K 31/50 (2006.01) C07D 403/12 (2006.01)
A61P 1/16 (2006.01)

(21) International Application Number:

PCT/US2024/034827

(22) International Filing Date:

20 June 2024 (20.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/509,267 20 June 2023 (20.06.2023) US

(71) Applicant: **SAGIMET BIOSCIENCES INC.** [US/US];
155 Bovet Road, Suite 303, San Mateo, California 94402
(US).

(72) Inventors: **O'FARRELL, Anne-Marie**; c/o Sagimet Bio-
sciences Inc., 155 Bovet Road, Suite 303, San Mateo, Cal-
ifornia 94402 (US). **KEMBLE, George**; c/o Sagimet Bio-
sciences Inc., 155 Bovet Road, Suite 303, San Mateo, Cal-
ifornia 94402 (US). **TSAL, Wen-Wei**; c/o Sagimet Bio-

sciences Inc., 155 Bovet Road, Suite 303, San Mateo, Cal-
ifornia 94402 (US).

(74) Agent: **KIM, Gina J.** et al.; Goodwin Procter LLP, 100
Northern Avenue, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: COMBINATION THERAPIES OF FASN INHIBITORS WITH THYROID HORMONE RECEPTOR AGONISTS




FIG. 1A

(57) Abstract: Therapeutic combinations of fatty acid synthesis modulators and thyroid hormone receptor agonists are provided. The combinations may be used to treat disorders including metabolic disorders and liver disorders, such as nonalcoholic steatohepatitis/metabolic dysfunction-associated steatohepatitis (NASH/MASH).

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*